Sotera Health (SHC) shares were in focus after the company reported stronger fourth quarter and full year 2025 earnings and provided new 2026 revenue guidance, outlining expected net revenues of US$1.233b to US$1.251b.

The recent earnings beat, new 2026 revenue guidance and upcoming leadership change around the General Counsel role arrive after a softer patch for the stock, with a 30 day share price return of 10.32% decline and a 1 year total shareholder return of 30.31%. Short term momentum has cooled while longer term holders are still ahead.

If this update has you thinking about where else growth and risk could be priced differently, it might be a good moment to scan our list of 27 healthcare AI stocks as a fresh set of healthcare ideas.

With SHC trading at US$16.25, sitting at a discount to analyst price targets and an indicated gap to some intrinsic estimates, the key question is whether this reflects undervaluation or whether the market already expects future growth.

Price-to-Earnings of 59.3x: Is it justified?

On a headline basis, Sotera Health looks expensive, with a P/E of 59.3x at the last close of $16.25, especially given that it screens as 50.2% below one intrinsic estimate and trades at a discount to analyst targets.

The P/E multiple compares the company’s share price to its earnings per share, so a higher figure usually signals that investors are paying more for each dollar of current earnings.

For Sotera Health, the high P/E sits alongside a forecast that earnings could grow 34.99% per year and that earnings growth is expected to be significantly above the broader US market. A discounted cash flow view suggests the shares are trading below an estimate of future cash flow value at $32.64.

Against peers, the gap is clear. Sotera Health’s 59.3x P/E sits above the US Life Sciences industry average of 35.2x and also above a peer average of 49.4x. An estimated fair P/E of 26x indicates a level the market could move toward if expectations cool.

Result: Price-to-Earnings of 59.3x (OVERVALUED)

However, the premium 59.3x P/E, recent 1-year gains of 30.31%, and a 5-year total return of a 39.09% decline leave little room for earnings disappointment.

Another View: Cash Flows Tell a Different Story

While the 59.3x P/E points to a rich price tag, our DCF model paints almost the opposite picture. On this view, SHC at $16.25 sits 50.2% below an estimated future cash flow value of $32.64, which frames the current price as potentially undervalued rather than stretched.

That gap suggests the market could be putting a heavier weight on earnings quality concerns and balance sheet risk than on the 34.99% forecast earnings growth. For you, the real question is whether cash flows or headline multiples better capture the risk you care about most.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sotera Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of high multiples, cash flow upside, and mixed past returns feels like a close call, it is worth checking the full picture yourself and moving quickly before sentiment shifts, including the 4 key rewards and 3 important warning signs that highlight where investors see both concern and potential upside.

Looking for more investment ideas?

If you are serious about sharpening your watchlist, do not stop at one company. Use focused stock lists to quickly spot opportunities that better match your style.

• Target potential mispricings by scanning our hand picked set of 1 high quality undervalued stocks that pair solid fundamentals with compressed expectations.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores designed for investors who want steadier business profiles and fewer financial red flags.
• Get ahead of the crowd by checking a screener containing 24 high quality undiscovered gems that highlights quality companies still flying under most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.